[Reflux esophagitis].
Gastroesophageal reflux disease (GERD) is one of the most prevalent diseases in the industrialized countries. Approximately 15-25% of adults suffer from reflux symptoms, characterized mainly by heartburn and/or regurgitation. Currently, antisecretory medication with proton pump inhibitors (PPI) or antireflux surgery are the established options for GERD-treatment. PPI are the therapeutic gold standard in acute, long-term or on-demand therapy of GERD. Since PPI do not restore the antireflux barrier but merely suppress acid secretion a life-long tablet adherence is required in most cases. In view of limitations of PPI and the potential risks of laparoscopic surgery, several endoscopic antireflux techniques were developed and may evolve as a valuable third option. However, so far objective long-term data are lacking for choosing the appropriate patient who will benefit most from endoluminal antireflux therapy.
Schiefke
I
I
Medizinische Klinik und Poliklinik II, Universität Leipzig.
Mössner
J
J
Caca
K
K
D000328:Adult; D000863:Antacids / Q000008:administration & dosage; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003430:Cross-Sectional Studies; D004942:Esophagitis, Peptic / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D018662:Fundoplication; D005745:Gastric Acidity Determination; D006801:Humans; D010535:Laparoscopy; D019736:Prostheses and Implants; D054328:Proton Pump Inhibitors; D055502:Secondary Prevention; D013536:Suture Techniques; D016896:Treatment Outcome
D000863:Antacids; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors